![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Aortic aneurysms (AAs) are without effective pharmacologic therapy, in clinical usage, in part because of the limited understanding of factors leading to AA development.
Objective: The objectives of this study were to examine the evidence that cigarette smoking induces AAs through altering matrix metalloproteinases (MMP) and the molecular biology/pharmacology that maybe involved in this effect.
Methods: A systematic search was conducted to identify studies that examined the links between cigarette smoke, MMP and AAs.
Results: Eleven studies were identified. There was consistency, between studies. They found that cigarette smoke, nicotine or tobacco products increased aortic dimension and the proportion of AAs. Nicotine and tobacco constituents induced MMPs: MMP-1, MMP-2, MMP-8, MMP-9 and MMP-12 but with different levels of consistency. The molecular mechanisms involved in the pathogenesis of cigarette-induced AA formation, ranked according to the consistency of evidence include JNK, AMPK-2, Jak Stat, and mTOR/p70Sk and PTEN pathways.
Conclusion: Nicotine and tobacco constituents translate the exposure to cigarette smoke into increased MMP expression through various molecular mechanisms whose interruption can form the basis for pharmacologic management of AAs.
Keywords: Aortic aneurysm, cigarette smoke, tobacco products, matrix metalloproteinases, JNK, AMPK-2, Jak Stat, mTOR/p70Sk PTEN.
Current Vascular Pharmacology
Title:The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm
Volume: 14 Issue: 6
Author(s): Simon W. Rabkin
Affiliation:
Keywords: Aortic aneurysm, cigarette smoke, tobacco products, matrix metalloproteinases, JNK, AMPK-2, Jak Stat, mTOR/p70Sk PTEN.
Abstract: Background: Aortic aneurysms (AAs) are without effective pharmacologic therapy, in clinical usage, in part because of the limited understanding of factors leading to AA development.
Objective: The objectives of this study were to examine the evidence that cigarette smoking induces AAs through altering matrix metalloproteinases (MMP) and the molecular biology/pharmacology that maybe involved in this effect.
Methods: A systematic search was conducted to identify studies that examined the links between cigarette smoke, MMP and AAs.
Results: Eleven studies were identified. There was consistency, between studies. They found that cigarette smoke, nicotine or tobacco products increased aortic dimension and the proportion of AAs. Nicotine and tobacco constituents induced MMPs: MMP-1, MMP-2, MMP-8, MMP-9 and MMP-12 but with different levels of consistency. The molecular mechanisms involved in the pathogenesis of cigarette-induced AA formation, ranked according to the consistency of evidence include JNK, AMPK-2, Jak Stat, and mTOR/p70Sk and PTEN pathways.
Conclusion: Nicotine and tobacco constituents translate the exposure to cigarette smoke into increased MMP expression through various molecular mechanisms whose interruption can form the basis for pharmacologic management of AAs.
Export Options
About this article
Cite this article as:
Rabkin W. Simon, The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160625091205
DOI https://dx.doi.org/10.2174/1570161114666160625091205 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interleukin-10 in the Vasculature: Pathophysiological Implications
Current Vascular Pharmacology Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]
Current Pharmaceutical Design Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm – What Does the Evidence Show?
Current Vascular Pharmacology Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Prevention of Intracerebral Haemorrhage
Current Drug Targets Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Transcription Factor MAZ Potentiates the Upregulated NEIL3-mediated Aerobic Glycolysis, thereby Promoting Angiogenesis in Hepatocellular Carcinoma
Current Cancer Drug Targets Mechanisms of Inflammatory Atherosclerosis in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Editorial: [Hot Topics: The Blood Brain Barrier in Stroke]
Current Pharmaceutical Design Update on the Imaging Techniques in the Diagnosis of Diabetic Retinopathy
Current Diabetes Reviews Prophylactic Neuroprotection
Current Drug Targets The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) Re: ‘Re. Renal Function Impairment in Patients Undergoing Elective EVAR vs Elective Open Repair During Follow up Period: A Systematic Review of the Literature’
Current Vascular Pharmacology